Rare diseases collectively affect more than 300 million people worldwide.

Patients and families living with rare diseases often face delayed diagnosis, limited awareness, and restricted access to innovative therapies. Nexa Pharm supports initiatives aimed at improving disease awareness, stakeholder collaboration, and healthcare access pathways within the Azerbaijan healthcare ecosystem.

Selected Experience

• Supported inclusion of orphan medicines into the national orphan drug list, enabling access without standard price registration and conventional national regulatory approval pathways within approximately 3 months.

  https://e-qanun.az/framework/36286

• Supported patient identification initiatives for rare diseases in Azerbaijan.

• Supported market entry preparation for rare disease therapies in Azerbaijan.

• Collaborated with national clinical experts, professional associations, and patient advocacy groups.

• Organized educational and market access activities across selected rare disease areas.

• Assisted discussions with healthcare authorities regarding access pathways for high-cost specialty treatments.

• Supported disease awareness initiatives aimed at increasing understanding of rare diseases, highlighting challenges faced by patients, and promoting stakeholder engagement to improve prioritization within the national healthcare agenda.